The Effects of Smooth Muscle Calponin on the Strong and Weak Myosin Binding Sites of F-actin*

  1. Mohammed EL-Mezgueldi and
  2. Steven B. Marston
  1. From the Department of Cardiac Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, United Kingdom
  1. To whom correspondence and reprint requests should be addressed. Tel.: 44-171-352-8121 (ext. 3300); Fax: 44-171-823-3392. E-mail: m.elmezgueldi{at}ic.ac.uk.

Abstract

We have investigated the mechanism of inhibition of the actomyosin MgATPase by the smooth muscle protein calponin. We have shown previously the specific interaction of calponin with Glu334 of actin (EL-Mezgueldi, M., Fattoum, A., Derancourt, J., and Kassab, R. (1992) J. Biol. Chem. 267, 15943-15951). This residue is within the sequence 332-334, which has been proposed to be an important part of the strong myosin binding site (Rayment, I., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993) Science 261, 58-65). Therefore, we suggested that calponin will affect the strong binding actin-myosin interaction. To test this hypothesis we have investigated the effect of calponin on the strong binding of S-1·MgAMP-PNP (5′-adenylyl imidodiphosphate) and on the weak binding of S-1·MgADP·Pi to actin. We found that an inhibitory concentration of calponin decreased the binding of S-1·MgAMP-PNP to actin but had no effect on the binding of S-1·MgADP·Pi. Similar results were obtained with skeletal muscle and smooth muscle S-1. In competition experiments calponin was found to displace S-1·MgAMP-PNP and S-1·MgADP but not S-1·MgADP·Pi from the actin filament. S-1 displaced calponin from actin in the rigor state, in the presence of MgADP, and in the presence of MgAMP-PNP. We conclude that calponin inhibits the actin activated S-1 ATPase by blocking a strong S-1 binding site on actin and does not block the weak binding site.

Footnotes

  • * This research was supported by a grant from the Wellcome Trust. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • 1 The abbreviations used are:

    S-1

    chymotryptic subfragment-1 of myosin

    AMP-PNP

    5′-adenylyl imidodiphosphate

    PIPES

    1,4-piperazinediethanesulfonic acid

    DTT

    1,4-dithio-DL-threitol.

    • Received March 12, 1996.
    • Revision received August 19, 1996.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement